Kodiak Sciences Inc. (NASDAQ: KOD) shares jumped after the company reported positive clinical trial data for its investigational eye drug, reviving the story around its…
Novocure (NASDAQ: NVCR) shares jumped 5% on Thursday following the announcement of encouraging topline results from its Phase 2 PANOVA-4 clinical trial. The study evaluated…
Inspire Medical Systems Inc. (NYSE: INSP) just removed a key friction point in its obstructive sleep apnea (OSA) story, winning expanded FDA approval that allows…
Gene therapies for hereditary hearing loss are emerging as one of the most compelling niches in an otherwise battered gene therapy landscape, giving investors a…
Gilead Sciences Inc. (NASDAQ: GILD) has agreed to acquire Ouro Medicines for 1.675 billion dollars in upfront cash, plus up to 500 million dollars in…
March 23, 2026
Pfizer Is Pushing Forward on a Lyme Disease Vaccine — Even After Missing Its Trial Goal
Pfizer (NYSE: PFE) and French biotech partner Valneva (Nasdaq: VALN) are moving toward regulatory submissions for their Lyme disease vaccine candidate, a decision that’s as…
Cencora (NYSE: COR) is making its biggest move yet in specialty eye care, agreeing to acquire the retina business of EyeSouth Partners for $1.1 billion,…
Spectral AI, Inc. (NASDAQ: MDAI) recently announced a substantial funding milestone through its ongoing partnership with the United States federal government. This $31.7 million award…
Shares of Allurion Technologies Inc. (ticker: ALUR) are rebounding today, recently up roughly 30% and trading around $0.75 as bargain hunters step into this now‑OTC obesity‑care name following its NYSE…
March 18, 2026
Fulgent Genetics Closes Dual Pathology Deal
Fulgent Genetics ( NASDAQ: FLGT) has finalized its acquisition of two specialty pathology laboratories — Bako Diagnostics and StrataDx, for approximately $56.9 million in cash,…
March 17, 2026
Candel Therapeutics Gains Momentum as Lead Cancer Therapy Advances Across Multiple Trials
Candel Therapeutics, Inc. (NASDAQ: CADL) continues to advance its lead oncology program following updated mid-stage clinical data for its investigational therapy CAN-2409 (aglatimagene besadenovec). The…
Structure Therapeutics Inc. (NASDAQ: GPCR) just delivered some of the strongest weight‑loss data yet for an oral GLP‑1, instantly elevating its M&A appeal in the…